ストックスクリーナーアプリを入手
34.43
0.35%
0.12
アフターアワーズ：
34.43
前日終値:
$34.31
開ける：
$34.34
24時間の取引高:
1.74M
Relative Volume:
0.75
時価総額：
$4.20B
収益：
$1.24B
当期純損益:
$209.00M
株価収益率:
20.73
EPS:
1.6605
ネットキャッシュフロー:
$-94.86M
1週間 パフォーマンス:
+6.83%
1か月 パフォーマンス:
+18.85%
6か月 パフォーマンス:
+38.22%
1年 パフォーマンス:
+197.58%
1日の値動き範囲:
$34.00
$34.75
1週間の範囲:
$32.34
$35.34
52週間の値動き範囲:
$10.63
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
名前
Indivior Pharmaceuticals Inc
セクター
電話
804-379-1090
住所
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
34.43 | 4.18B | 1.24B | 209.00M | -94.86M | 1.6605 |
TAK
Takeda Pharmaceutical Co Adr
|
16.41 | 51.68B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.65 | 49.57B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.47 | 42.18B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.62 | 36.40B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
569.11 | 24.85B | 3.18B | 1.33B | 1.04B | 27.90 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-22 | 再開されました | Jefferies | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-23 | 開始されました | Piper Sandler | Overweight |
| 2024-04-03 | 開始されました | Craig Hallum | Buy |
| 2023-07-13 | 開始されました | Northland Capital | Outperform |
すべてを表示
Indivior Pharmaceuticals Inc (INDV) 最新ニュース
Vanguard Portfolio Management reports 7.99M Indivior shares (INDV) - Stock Titan
Indivior plans $400M convertible senior notes offering - MSN
Evaluating Indivior Pharmaceuticals (NasdaqGS:INDV) After New ASAM 2026 Data On Sublocade Effectiveness - simplywall.st
How much upside is left in Indivior Pharmaceuticals Inc. (INDV)? Wall Street analysts think 45.99% - MSN
Is Indivior Pharmaceuticals Inc (INDV) Overvalued After 3.2% Ral - GuruFocus
Vanguard Capital Management holds 5.35% of Indivior (NASDAQ: INDV) - Stock Titan
Indivior Pharmaceuticals (INDV) Jumps 6.2% to $35.27 - AlphaStreet
Organon Shares Rally 16% in Premarket as Sun Pharma Announces Buyout - TradingView
Indivior Pharmaceuticals Inc. (INDV): Billionaire Howard Marks Trims Stake - Insider Monkey
How Investors Are Reacting To Indivior (INDV) Real-World SUBLOCADE Data On Remission-Focused OUD Treatment - Yahoo Finance
Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV) - MSN
INDV Price Today: Indivior Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Indivior (INDV) Showcases Research on Buprenorphine at Addiction Medicine Conference - GuruFocus
Indivior Pharmaceuticals Collaborates with Virginia Tech on Research Highlighting Remission and Treatment Outcomes in Opioid Use Disorder at ASAM Conference - Quiver Quantitative
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a ... - Caledonian Record
Indivior Presents New Real-World Data at ASAM 2026 Annual - GlobeNewswire
Grail and Indivior PLC come out on top in healthcare quant picks ahead of Q4 earnings - MSN
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
A Look at Indivior Pharmaceuticals Inc (INDV) After 3.6% Gain -- GF Value $21.89 vs Price $33.39 - GuruFocus
Does Indivior (INDV) Survey Support For Long-Acting Buprenorphine Strengthen Its Criminal Justice Strategy? - Sahm
Indivior Pharmaceuticals Inc. (INDV) Tops Q4 Earnings and Revenue Estimates - Eastern Progress
Indivior Pharmaceuticals Inc (INDV) Shares Fall 3.1% -- What GF Score of 69 Tells Investors - GuruFocus
Indivior Pharmaceuticals (INDV) Valuation Check After Recent Share Price Volatility - Yahoo Finance
Indivior PLC Survey Highlights Correctional Leaders' Support for Long-Acting Injectable Buprenorphine to Mitigate MOUD Diversion - Quiver Quantitative
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse - GlobeNewswire
INDV Insider Filing: Barry Patrick Restricted Stock Units April 2026 - Meyka
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug - The Globe and Mail
Assessing Indivior (INDV) Valuation After New SUBLOCADE Study In Correctional Healthcare - Sahm
Cipher Mining Stock, Five Below, Indivior Among 10 New Stocks On IBD Watchlists - Investor's Business Daily
A Look at Indivior Pharmaceuticals Inc (INDV) After 3.5% Gain -- GF Value $21.93 vs Price $31.60 - GuruFocus
Has The Strong Three-Year Run Left Indivior Pharmaceuticals (INDV) Priced Too Richly Today? - Yahoo Finance
Indivior Lends Voice to Help Raise Awareness of Substance Use Di - GuruFocus
If You Invested $1,000 in Indivior Pharmaceuticals Inc. (INDV) - Stock Titan
Indivior Pharmaceuticals Inc (INDV) Stock Down 5.5% but Still Ov - GuruFocus
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results - TradingView — Track All Markets
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200 - TradingView
How Much Upside is Left in Indivior Pharmaceuticals Inc. (INDV)? Wall Street Analysts Think 45.99% - Yahoo Finance
Indivior to Report Q1 2026 Earnings, Host Webcast - National Today
Indivior to Report First Quarter 2026 Financial Results - National Today
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th - The Manila Times
Is Indivior Pharmaceuticals (INDV) Stock Breaking Out | Price at $30.47, Up 0.16%Target Price - Cổng thông tin điện tử Tỉnh Sơn La
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - TradingView
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - zacks.com
Indivior Pharmaceuticals Inc (INDV) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
0.51%
大文字化:
|
ボリューム (24 時間):